Inventor · disambiguated record
Lars Holten-Andersen
Also filed as: HOLTEN-ANDERSEN LARS
6 granted patents·8 pending applications·26 citations·filing 2017–2025
80Inventor score
Files withASCENDIS PHARMA BONE DISEASES AS8ASCENDIS PHARMA ONCOLOGY DIV A/S3ASCENDIS PHARMA GROWTH DISORDERS AS2ASCENDIS PHARMA AS1
Top patents by PatentIndex Score
14 records- 0195US11857603B2PTH compounds with low peak-to-trough ratiosASCENDIS PHARMA BONE DISEASES AS·Filed 2022·Granted Jan 2, 2024·5 cites·12 claims
- 0292US11759504B2PTH compounds with low peak-to-trough ratiosASCENDIS PHARMA BONE DISEASES AS·Filed 2017·Granted Sep 19, 2023·6 cites·12 claims
- 0391US11590207B2Dosage regimen for a controlled-release PTH compoundASCENDIS PHARMA BONE DISEASES AS·Filed 2017·Granted Feb 28, 2023·9 cites·5 claims
- 0487US12295989B2Controlled-release PTH compoundASCENDIS PHARMA BONE DISEASES AS·Filed 2024·Granted May 13, 2025·0 cites·5 claims
- 0586US11564974B2Combination therapy with controlled-release CNP agonistsASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2017·Granted Jan 31, 2023·6 cites·7 claims
- 0680US2024173385A1PTH Compounds with Low Peak-To-Trough RatiosASCENDIS PHARMA BONE DISEASES AS·Filed 2023·Application pending·0 cites
- 0777US2025302924A1Controlled-Release PTH CompoundASCENDIS PHARMA BONE DISEASES AS·Filed 2025·Application pending·0 cites
- 0868US2023302091A1Combination Therapy with Controlled-Release CNP AgonistsASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2022·Application pending·0 cites
- 0967US2020360488A1Pth compounds with low peak-to-trough ratiosASCENDIS PHARMA BONE DISEASES AS·Filed 2020·Application pending·0 cites
- 1050US2021330798A1Treatment of infectionsASCENDIS PHARMA AS·Filed 2019·Application pending·0 cites
- 1148US12453778B2Incremental dose finding in controlled-release PTH compoundsASCENDIS PHARMA BONE DISEASES AS·Filed 2017·Granted Oct 28, 2025·0 cites·8 claims
- 1245US2022054476A1Sustained local drug levels for innate immune agonistsASCENDIS PHARMA ONCOLOGY DIV A/S·Filed 2020·Application pending·0 cites
- 1345US2022054478A1Minimization of systemic inflammationASCENDIS PHARMA ONCOLOGY DIV A/S·Filed 2020·Application pending·0 cites
- 1445US2022054477A1Induction of sustained local inflammationASCENDIS PHARMA ONCOLOGY DIV A/S·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Lars Holten-Andersen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →